Where are we now? The promises and pitfalls of solid tumor CAR-T therapy
CAR T-cell therapy (CAR-T) has emerged as a therapeutic option with the ability to infiltrate and modulate the tumor microenvironment and control tumor growth....
Oncology consulting with cutting-edge strategies and comprehensive expertise
The treatment, policies, and study of oncology continue to undergo rapid changes and evolution, with each year bringing new opportunities and challenges for existing and new treatments. CRA positions itself on the cutting edge of the field, staying abreast of the latest issues and developments and allowing us to provide actionable, future-focused strategies for our clients.
CRA’s knowledge base stems from hundreds of engagements on solid and hematological tumors, working with clients on small molecules, monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), cell therapies, oncology vaccines, and the increasing range of combination approaches to treating cancer.
Why CRA for your strategic partner in oncology?
Engagements
- 01US go-to-market business strategy and market mapping for cell therapies in oncologyA team of CRA Life Sciences consultants successfully assisted the client, an academic medical center (AMC), by using market research to identify key factors...View engagement
- 02Long-term strategic partner in bladder cancerWe formed a long-term, multi-project partnership with a leading manufacturer that was looking to establish its new product as standard of care in bladder...View engagement
- 03Pricing and market access potential for doublet and triplet regimens in endometrial cancerCRA’s pricing and market access experts partnered with a global value and access team to develop the pricing and access strategy for novel combination...View engagement